Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Acute Lymphoblastic Leukemia

November 16, 2015

Join Dan Douer, MD and Jae Park, MD from Memorial Sloan Kettering Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to acute lymphoblastic leukemia (ALL).

ALL is a heterogeneous hematologic disease characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs. The NCCN Guidelines stratify patients with ALL by the presence of the Philadelphia chromosome and then by age, with adolescents and young adults defined as those between the ages of 15 and 39 years and adults defined as 40 years of age and older. The NCCN Guidelines further classify ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; and supportive care considerations.

There are subsets of patients for whom current treatment options remain ineffective. Survival outcomes are poor when the disease is relapsed/refractory, and even in patients with relapsed/refractory disease who achieve a complete response, the majority will not be durable. Therefore, improvement in the treatment options for this subset of patients with ALL is necessary.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the components of risk assessment and stratification for risk-adapted therapy
  • Summarize the current and emerging treatment options for acute lymphoblastic leukemia
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
11/13/2015
Course expires: 
01/31/2016
Event starts: 
11/16/2015 - 2:00pm
Event ends: 
11/16/2015 - 3:00pm
Cost:
$0.00

Dan Douer, MD
Memorial Sloan Kettering Cancer Center

Jae Park, MD
Memorial Sloan Kettering Cancer Center

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
11/13/2015
Course expires: 
01/31/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing